Singapore, Aug. 23 -- CStone Pharmaceuticals, on 23 August 2019, announced that the Company has recently received ethics approval from the Human Research Ethics Committee in Australia for the Phase I clinical trial of CS3002, and Australia's Therapeutic Goods Administration (TGA) has acknowledged the electronic Clinical Trial Notification (eCTN) the Company submitted for the trial. This clinical trial is an open-label, multi-dose, dose-escalation, and dose-expansion Phase I clinical study designed to evaluate the safety, tolerability, pharmacokinetics, and anti-tumour efficacy of CS3002 in patients with advanced solid tumours.

Being developed by CStone, CS3002 is a selective inhibitor of the cyclin-dependent kinases 4 and 6 (CDK4/6). Ind...